Seroatlas · Human Serome Atlas

SUMO1

Small ubiquitin-related modifier 1

Also known as: GMP1, OFC10, PIC1, SMT3C, SMT3H3, SUMO-1, SUMO1_HUMAN, UBL1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P63165
Gene
SUMO1
Ensembl
ENSG00000116030
Chromosome
2
Canonical length
101 aa
Protein class
Disease related genes, Human disease related genes, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nuclear membrane,Nucleoli,Nuclear bodies

OverviewNCBI Gene

This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last four amino acids of the carboxy-terminus have been cleaved off. Several pseudogenes have been reported for this gene. Alternate transcriptional splice variants encoding different isoforms have been characterized. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

101 residues, UniProt reviewed canonical sequence.

>P63165|SUMO1
     1  MSDQEAKPST EDLGDKKEGE YIKLKVIGQD SSEIHFKVKM TTHLKKLKES YCQRQGVPMN
    61  SLRFLFEGQR IADNHTPKEL GMEEEDVIEV YQEQTGGHST V

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SUMO1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.41
Highest tissue expression
163 nTPM

Expression across tissuesHPA

Tissue

  • liver: 163 nTPM
  • bone marrow: 126 nTPM
  • kidney: 110 nTPM
  • thymus: 104 nTPM
  • skeletal muscle: 101 nTPM
  • cerebral cortex: 99 nTPM

Single-cell type

  • esophageal apical cells: 342 nCPM
  • parietal cells: 322 nCPM
  • extravillous trophoblasts: 321 nCPM
  • basal keratinocytes: 293 nCPM
  • suprabasal keratinocytes: 291 nCPM
  • migrating cytotrophoblasts: 290 nCPM

Immune cell

  • total PBMC: 395 nTPM
  • T-reg: 330 nTPM
  • eosinophil: 285 nTPM
  • memory B-cell: 278 nTPM
  • neutrophil: 258 nTPM
  • NK-cell: 247 nTPM

Brain region

  • cerebral cortex: 100 nTPM
  • cerebellum: 94 nTPM
  • hypothalamus: 88 nTPM
  • white matter: 87 nTPM
  • choroid plexus: 86 nTPM
  • basal ganglia: 84 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SUMO1.

Disease | AllUniProt

Conditions SUMO1 is implicated in, by any mechanism.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.46
gnomAD pLI
0.86
gnomAD missense Z
1.51
DepMap mean gene effect
-0.18
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SUMO1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SUMO1 as an antibody target. Whether an autoantibody or antibody against SUMO1 could matter depends on whether native SUMO1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SUMO1 is annotated at the cell surface, where native SUMO1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SUMO1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SUMO1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...